迪哲醫藥:DZD1516在乳腺癌領域取得的臨牀前和I期臨牀研究成果在國際期刊《Breast Cancer Research》發表
格隆匯7月9日丨迪哲醫藥(688192.SH)公佈,公司自主研發的DZD1516是一種高選擇性HER2酪氨酸激酶抑制劑(TKI),具備完全穿透血腦屏障的能力。近日,DZD1516在乳腺癌領域取得的臨牀前和I期臨牀研究成果在國際期刊《Breast Cancer Research》發表,進一步證明了DZD1516的藥物潛力和研究價值。
《Breast Cancer Research》(《乳腺癌研究》)是全球乳腺癌領域的重要研究期刊,發表乳腺癌領域基礎研究、轉化科學和臨牀應用的全球重大研究成果。在腫瘤領域中,該期刊在全球範圍內的引用率和關注度位居前 30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.